TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK

BMC Immunol. 2010 Nov 23:11:57. doi: 10.1186/1471-2172-11-57.

Abstract

Background: Cytokines of the transforming growth factor β (TGF-β) superfamily exert effects on proliferation, apoptosis and differentiation in various cell types. Cancer cells frequently acquire resistance to the anti-proliferative signals of TGF-β, which can be due to mutations in proteins of the signalling cascade. We compared the TGF-β-related signalling properties in B-cell lymphoma cell lines that were sensitive or resistant to TGF-β-induced anti-proliferative effects.

Results: TGF-β sensitive cell lines expressed higher cell surface levels of the activin receptor-like kinase 5 (Alk-5), a TGF-β receptor type 1. The expression levels of the other TGF-β and bone morphogenetic protein receptors were comparable in the different cell lines. TGF-β-induced phosphorylation of Smad2 was similar in TGF-β sensitive and resistant cell lines. In contrast, activation of Smad1/5 was restricted to cells that were sensitive to growth inhibition by TGF-β. Moreover, with activin A we detected limited anti-proliferative effects, strong phosphorylation of Smad2, but no Smad1/5 phosphorylation. Up-regulation of the TGF-β target genes Id1 and Pai-1 was identified in the TGF-β sensitive cell lines. Constitutive phosphorylation of MAPK p38 was restricted to the TGF-β sensitive cell lines. Inhibition of p38 MAPK led to reduced sensitivity to TGF-β.

Conclusions: We suggest that phosphorylation of Smad1/5 is important for the anti-proliferative effects of TGF-β in B-cell lymphoma. Alk-5 was highly expressed in the sensitive cell lines, and might be important for signalling through Smad1/5. Our results indicate a role for p38 MAPK in the regulation of TGF-β-induced anti-proliferative effects.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Bone Morphogenetic Protein Receptors / metabolism
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Enzyme Activation / drug effects
  • Growth Inhibitors / pharmacology
  • Humans
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / immunology*
  • Lymphoma, B-Cell / pathology
  • Phosphorylation
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism
  • Receptor, Transforming Growth Factor-beta Type I
  • Receptors, Transforming Growth Factor beta / genetics
  • Receptors, Transforming Growth Factor beta / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • Smad1 Protein / immunology
  • Smad1 Protein / metabolism*
  • Smad5 Protein / immunology
  • Smad5 Protein / metabolism*
  • Transforming Growth Factor beta / pharmacology*
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Growth Inhibitors
  • Receptors, Transforming Growth Factor beta
  • Smad1 Protein
  • Smad5 Protein
  • Transforming Growth Factor beta
  • Protein Serine-Threonine Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Bone Morphogenetic Protein Receptors
  • Receptor, Transforming Growth Factor-beta Type I
  • TGFBR1 protein, human